

Francesco Paneni

List of Publications by Citations

Source: <https://exaly.com/author-pdf/709934/francesco-paneni-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

106
papers

3,725
citations

31
h-index

59
g-index

121
ext. papers

4,633
ext. citations

5.5
avg. IF

5.81
L-index

#	Paper	IF	Citations
106	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. <i>European Heart Journal</i> , 2013 , 34, 2436-43	9.5	597
105	The Aging Cardiovascular System: Understanding It at the Cellular and Clinical Levels. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1952-1967	15.1	262
104	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. <i>European Heart Journal</i> , 2013 , 34, 2444-52	9.5	213
103	Gene silencing of the mitochondrial adaptor p66(Shc) suppresses vascular hyperglycemic memory in diabetes. <i>Circulation Research</i> , 2012 , 111, 278-89	15.7	169
102	Ageing, metabolism and cardiovascular disease. <i>Journal of Physiology</i> , 2016 , 594, 2061-73	3.9	164
101	AngiomiR-126 expression and secretion from circulating CD34(+) and CD14(+) PBMCs: role for proangiogenic effects and alterations in type 2 diabetics. <i>Blood</i> , 2013 , 121, 226-36	2.2	146
100	Adverse epigenetic signatures by histone methyltransferase Set7 contribute to vascular dysfunction in patients with type 2 diabetes mellitus. <i>Circulation: Cardiovascular Genetics</i> , 2015 , 8, 150-8		106
99	Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. <i>Clinical Science</i> , 2009 , 116, 467-77	6.5	106
98	Impact of Glycemic Variability on Chromatin Remodeling, Oxidative Stress, and Endothelial Dysfunction in Patients With Type 2 Diabetes and With Target HbA Levels. <i>Diabetes</i> , 2017 , 66, 2472-2482	9.9	105
97	MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart. <i>European Heart Journal</i> , 2016 , 37, 572-6	9.5	102
96	Insulin resistance, diabetes, and cardiovascular risk. <i>Current Atherosclerosis Reports</i> , 2014 , 16, 419	6	99
95	Deletion of the activated protein-1 transcription factor JunD induces oxidative stress and accelerates age-related endothelial dysfunction. <i>Circulation</i> , 2013 , 127, 1229-40, e1-21	16.7	73
94	SIRT1, p66(Shc), and Set7/9 in vascular hyperglycemic memory: bringing all the strands together. <i>Diabetes</i> , 2013 , 62, 1800-7	0.9	73
93	Endothelial overexpression of LOX-1 increases plaque formation and promotes atherosclerosis in vivo. <i>European Heart Journal</i> , 2014 , 35, 2839-48	9.5	58
92	Right ventricular dysfunction in patients with end-stage renal disease. <i>American Journal of Nephrology</i> , 2010 , 32, 432-8	4.6	58
91	Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: insights in patients with diabetes. <i>European Heart Journal</i> , 2015 , 36, 817-28	9.5	57
90	Deletion of the ageing gene p66(Shc) reduces early stroke size following ischaemia/reperfusion brain injury. <i>European Heart Journal</i> , 2013 , 34, 96-103	9.5	56

89	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. <i>American Journal of Cardiology</i> , 2017 , 120, S17-S27	3	54
88	Epigenetic signatures and vascular risk in type 2 diabetes: a clinical perspective. <i>Atherosclerosis</i> , 2013 , 230, 191-7	3.1	54
87	Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena. <i>European Heart Journal</i> , 2018 , 39, 4150-4158	9.5	49
86	The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk. <i>Kidney International</i> , 2018 , 94, 49-59	9.9	43
85	Role of oxidative stress in endothelial insulin resistance. <i>World Journal of Diabetes</i> , 2015 , 6, 326-32	4.7	43
84	Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy. <i>European Heart Journal</i> , 2019 , 40, 997-1008	9.5	40
83	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. <i>American Journal of Medicine</i> , 2017 , 130, S18-S29	2.4	37
82	Interleukin-1 Mediates Arterial Thrombus Formation via NET-Associated Tissue Factor. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	37
81	Exercise training for patients with type 2 diabetes and cardiovascular disease: What to pursue and how to do it. A Position Paper of the European Association of Preventive Cardiology (EAPC). <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 709-727	3.9	36
80	Pin1 inhibitor Juglone prevents diabetic vascular dysfunction. <i>International Journal of Cardiology</i> , 2016 , 203, 702-7	3.2	35
79	Sirtuin 5 as a novel target to blunt blood-brain barrier damage induced by cerebral ischemia/reperfusion injury. <i>International Journal of Cardiology</i> , 2018 , 260, 148-155	3.2	34
78	Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity. <i>European Heart Journal</i> , 2019 , 40, 383-391	9.5	33
77	Post-ischaemic administration of the murine Canakinumab-surrogate antibody improves outcome in experimental stroke. <i>European Heart Journal</i> , 2018 , 39, 3511-3517	9.5	33
76	Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66. <i>International Journal of Cardiology</i> , 2018 , 268, 179-186	3.2	32
75	Molecular pathways of arterial aging. <i>Clinical Science</i> , 2015 , 128, 69-79	6.5	31
74	Genetic deletion of the adaptor protein p66Shc increases susceptibility to short-term ischaemic myocardial injury via intracellular salvage pathways. <i>European Heart Journal</i> , 2015 , 36, 516-26a	9.5	29
73	From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases. <i>European Heart Journal</i> , 2020 , 41, 3884-3899	9.5	29
72	Epigenetics and cardiovascular regenerative medicine in the elderly. <i>International Journal of Cardiology</i> , 2018 , 250, 207-214	3.2	29

71	Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis. <i>International Journal of Cardiology</i> , 2013 , 167, 2482-9	3.2	29
70	Endothelial SIRT6 blunts stroke size and neurological deficit by preserving blood-brain barrier integrity: a translational study. <i>European Heart Journal</i> , 2020 , 41, 1575-1587	9.5	26
69	Antihypertensive therapy in diabetes: the legacy effect and RAAS blockade. <i>Current Hypertension Reports</i> , 2011 , 13, 318-24	4.7	25
68	Targeting chromatin remodeling to prevent cardiovascular disease in diabetes. <i>Current Pharmaceutical Biotechnology</i> , 2015 , 16, 531-43	2.6	24
67	Assessment and pathophysiology of microvascular disease: recent progress and clinical implications. <i>European Heart Journal</i> , 2021 , 42, 2590-2604	9.5	24
66	Epigenetic Control of Mitochondrial Function in the Vasculature. <i>Frontiers in Cardiovascular Medicine</i> , 2020 , 7, 28	5.4	23
65	p66(Shc)-induced redox changes drive endothelial insulin resistance. <i>Atherosclerosis</i> , 2014 , 236, 426-9	3.1	23
64	Epigenetic processing in cardiometabolic disease. <i>Atherosclerosis</i> , 2019 , 281, 150-158	3.1	23
63	Endothelial LOX-1 activation differentially regulates arterial thrombus formation depending on oxLDL levels: role of the Oct-1/SIRT1 and ERK1/2 pathways. <i>Cardiovascular Research</i> , 2017 , 113, 498-507 ^{9.9}	9.9	22
62	Reprogramming ageing and longevity genes restores paracrine angiogenic properties of early outgrowth cells. <i>European Heart Journal</i> , 2016 , 37, 1733-7	9.5	22
61	Do diabetes, metabolic syndrome or their association equally affect biventricular function? A tissue Doppler study. <i>Hypertension Research</i> , 2013 , 36, 36-42	4.7	22
60	Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes. <i>Cardiovascular Diagnosis and Therapy</i> , 2014 , 4, 324-32	2.6	22
59	2013 ESC/EASD guidelines on the management of diabetes and cardiovascular disease: established knowledge and evidence gaps. <i>Diabetes and Vascular Disease Research</i> , 2014 , 11, 5-10	3.3	18
58	p66 Shc as the engine of vascular aging. <i>Current Vascular Pharmacology</i> , 2012 , 10, 697-9	3.3	18
57	An overview of the molecular mechanisms underlying development and progression of bicuspid aortic valve disease. <i>Journal of Molecular and Cellular Cardiology</i> , 2019 , 132, 146-153	5.8	15
56	Epigenetic modulation of tenascin C in the heart: implications on myocardial ischemia, hypertrophy and metabolism. <i>Journal of Hypertension</i> , 2019 , 37, 1861-1870	1.9	15
55	The epigenetic landscape in the cardiovascular complications of diabetes. <i>Journal of Endocrinological Investigation</i> , 2019 , 42, 505-511	5.2	15
54	Relation between right and left ventricular function in patients undergoing chronic dialysis. <i>Journal of Cardiovascular Medicine</i> , 2013 , 14, 289-95	1.9	14

53	Sirt6 deletion in bone marrow-derived cells increases atherosclerosis - Central role of macrophage scavenger receptor 1. <i>Journal of Molecular and Cellular Cardiology</i> , 2020 , 139, 24-32	5.8	13
52	Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies. <i>European Heart Journal</i> , 2021 , 42, 1940-1958	9.5	13
51	DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety. <i>Cardiovascular Diagnosis and Therapy</i> , 2015 , 5, 471-8	2.6	12
50	Hyperglycemia: a bad signature on the vascular system. <i>Cardiovascular Diagnosis and Therapy</i> , 2015 , 5, 403-6	2.6	12
49	Hyperglycemia Induces Myocardial Dysfunction via Epigenetic Regulation of JunD. <i>Circulation Research</i> , 2020 , 127, 1261-1273	15.7	12
48	Impact of dialysis modality on the appropriateness of left ventricular mass in patients with end-stage renal disease. <i>International Journal of Cardiology</i> , 2011 , 149, 250-252	3.2	11
47	Epigenetic Remodeling in Obesity-Related Vascular Disease. <i>Antioxidants and Redox Signaling</i> , 2021 , 34, 1165-1199	8.4	10
46	Atrial fibrillation in the cardiometabolic patient. <i>Minerva Medica</i> , 2019 , 110, 157-167	2.2	9
45	Characterisation of haemodynamic and metabolic abnormalities in the heart failure spectrum: the role of combined cardiopulmonary and exercise echocardiography stress test. <i>Minerva Cardiology and Angiology</i> , 2021 ,	2.4	9
44	Clinical SYNTAX score predicts outcomes of patients undergoing coronary artery bypass grafting. <i>American Heart Journal</i> , 2017 , 188, 118-126	4.9	8
43	Cardiomyocyte-Specific JunD Overexpression Increases Infarct Size following Ischemia/Reperfusion Cardiac Injury by Downregulating Sirt3. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 168-180	7	8
42	New Mechanisms of Vascular Dysfunction in Cardiometabolic Patients: Focus on Epigenetics. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020 , 27, 363-371	2.9	8
41	Abnormal regulation of renin angiotensin aldosterone system is associated with right ventricular dysfunction in hypertension. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 188-94	3.8	7
40	Inflammation in Metabolic Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 742178	5.4	7
39	The NO-donor MPC-1011 stimulates angiogenesis and arteriogenesis and improves hindlimb ischemia via a cGMP-dependent pathway involving VEGF and SDF-1. <i>Atherosclerosis</i> , 2020 , 304, 30-38	3.1	6
38	Empagliflozin across the stages of diabetic heart disease. <i>European Heart Journal</i> , 2018 , 39, 371-373	9.5	6
37	Regression of left ventricular hypertrophy with SGLT2 inhibitors. <i>European Heart Journal</i> , 2020 , 41, 3433-3436	9.5	5
36	PCSK9 in diabetes: sweet, bitter or sour?. <i>European Heart Journal</i> , 2019 , 40, 369-371	9.5	5

35	GLP-1-based therapies to boost autophagy in cardiometabolic patients: From experimental evidence to clinical trials. <i>Vascular Pharmacology</i> , 2019 , 115, 64-68	5.9	4
34	The vascular epigenome in patients with obesity and type 2 diabetes: opportunities for personalized therapies. <i>Vascular Biology (Bristol, England)</i> , 2020 , 2, H19-H28	2.9	4
33	Residual SYNTAX score following coronary artery bypass grafting. <i>European Journal of Cardio-thoracic Surgery</i> , 2017 , 51, 547-553	3	4
32	Deletion of fibroblast activation protein provides atheroprotection. <i>Cardiovascular Research</i> , 2021 , 117, 1060-1069	9.9	4
31	Sirtuin 5 promotes arterial thrombosis by blunting the fibrinolytic system. <i>Cardiovascular Research</i> , 2021 , 117, 2275-2288	9.9	3
30	Cell-specific epigenetic changes in atherosclerosis. <i>Clinical Science</i> , 2021 , 135, 1165-1187	6.5	3
29	A call for safety during electrophysiological procedures: US in, why not US out?. <i>Europace</i> , 2017 , 19, 2048-9	3.9	2
28	Epidemiology, Definition, and Diagnosis of Diabetes Mellitus 2015 , 3-12		2
27	Stakeholders in non-Vitamin K antagonist oral anticoagulants prescription: the case of Italy. <i>Europace</i> , 2016 , 18, 788	3.9	2
26	Diabetes and cardiovascular disease: let's push forward with translational research. <i>Cardiovascular Diagnosis and Therapy</i> , 2015 , 5, 407-11	2.6	2
25	Predictors of Successful Ultrasound Guided Femoral Vein Cannulation in Electrophysiological Procedures. <i>Journal of Atrial Fibrillation</i> , 2018 , 11, 2083	0.8	2
24	Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease-From Bench to Bedside. <i>Frontiers in Physiology</i> , 2021 , 12, 755060	4.6	2
23	MMP-2 knockdown blunts age-dependent carotid stiffness by decreasing elastin degradation and augmenting eNOS activation. <i>Cardiovascular Research</i> , 2021 ,	9.9	2
22	Intrinsic bleeding risk in patients with uninterrupted oral anticoagulation undergoing cardiac implantable electronic device procedures: a pilot study. <i>International Journal of Cardiology</i> , 2014 , 176, 1420-2	3.2	1
21	Mechanisms of Cardiovascular Aging. <i>Current Translational Geriatrics and Experimental Gerontology Reports</i> , 2013 , 2, 275-283		1
20	A case of thrombolysis in acute pulmonary embolism with right atrial thrombus: comparing current and past guidelines. <i>Internal and Emergency Medicine</i> , 2009 , 4, 497-500	3.7	1
19	Novel Lipids Targets in the Era of Metabolic Syndrome. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2009 , 16, 93-100	2.9	1
18	Role of the Nuclear Receptor Corepressor 1 (NCOR1) in Atherosclerosis and Associated Immunometabolic Diseases. <i>Frontiers in Immunology</i> , 2020 , 11, 569358	8.4	1

17	Disentangling the epigenetic landscape in cardiovascular patients: a path toward personalized medicine. <i>Minerva Cardiology and Angiology</i> , 2021 , 69, 331-345	2.4	1
16	Image integration guided ablation of left outflow tract ventricular tachycardia: Is coronary angiography still necessary?. <i>Indian Pacing and Electrophysiology Journal</i> , 2018 , 18, 73-75	1.5	1
15	A Once-and-Done Approach to the Lifelong Reduction of Elevated Cholesterol. <i>European Heart Journal</i> , 2021 , 42, 3820-3821	9.5	1
14	Adeno-Associated Virus-Mediated Gain-of-Function mPCSK9 Expression in the Mouse Induces Hypercholesterolemia, Monocytosis, Neutrophilia, and a Hypercoagulative State. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 718741	5.4	1
13	The Epigenome in Atherosclerosis. <i>Handbook of Experimental Pharmacology</i> , 2021 , 1	3.2	0
12	Sex-related differences in the ageing brain: time for precision medicine?. <i>Cardiovascular Research</i> , 2020 , 116, 1246-1248	9.9	0
11	Is tirzepatide in the surpass lane over GLP-1 receptor agonists for the treatment of diabetes?. <i>European Heart Journal</i> , 2021 , 42, 4211-4212	9.5	0
10	Diabetes and heart failure: from disease mechanisms to personalized care.. <i>Minerva Cardiology and Angiology</i> , 2022 , 70, 341-343	2.4	0
9	Authors'Reply to Dr. Schmitz and Dr. Brand comments on "Epigenetics and Cardiovascular Regenerative Medicine in the Elderly". <i>International Journal of Cardiology</i> , 2018 , 257, 274	3.2	
8	Thromboembolic Events Following Atrial Fibrillation Cardioversion and Ablation: What's the Culprit?. <i>Medicina (Lithuania)</i> , 2019 , 55,	3.1	
7	The Growing Importance of Socioeconomic Aspects in Cardiovascular Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007 , 14, 139-144	2.9	
6	Upcoming Challenges for Training in Cardiology. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007 , 14, 201-206	2.9	
5	The Microvolt T-Wave Alternans Test. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007 , 14, 213-219	2.9	
4	The Apelin/APJ System. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2006 , 13, 159-162	2.9	
3	Risk Stratification 2015 , 69-83		
2	Environment, Epigenetic Changes, and Cardiovascular Damage 2015 , 35-47		
1	Exploring RNA biomarkers in patients with acute myocarditis. <i>European Heart Journal</i> , 2021 , 42, 3425-3436	9.5	